Literature DB >> 18838297

Nonimmune cells in inflammatory bowel disease: from victim to villain.

Silvio Danese1.   

Abstract

Nonimmune cells have traditionally been viewed as target cells of the aberrant inflammatory process present in chronic immune-mediated conditions such as inflammatory bowel disease (IBD). However, the discovery that many of the functions traditionally attributed to immune cells are also performed by nonimmune cells has caused a shift to a multidirectional hypothesis in which nonimmune cells and acellular elements play active roles. Many types of interactions occur within this multidirectional system, and the difficulties associated with modeling these complex interactions currently limit our understanding of the cellular network that occurs in IBD. I describe the current knowledge of the roles played by nonimmune cells in the pathogenesis of IBD, as they emerge as crucial alternative targets for therapeutic intervention.

Entities:  

Mesh:

Year:  2008        PMID: 18838297     DOI: 10.1016/j.it.2008.07.009

Source DB:  PubMed          Journal:  Trends Immunol        ISSN: 1471-4906            Impact factor:   16.687


  21 in total

Review 1.  Important aspects of Toll-like receptors, ligands and their signaling pathways.

Authors:  Z L Chang
Journal:  Inflamm Res       Date:  2010-07-01       Impact factor: 4.575

Review 2.  Intestinal dendritic cells in the pathogenesis of inflammatory bowel disease.

Authors:  Sergio Rutella; Franco Locatelli
Journal:  World J Gastroenterol       Date:  2011-09-07       Impact factor: 5.742

Review 3.  Multipotent role of platelets in inflammatory bowel diseases: a clinical approach.

Authors:  Evangelos Voudoukis; Konstantinos Karmiris; Ioannis E Koutroubakis
Journal:  World J Gastroenterol       Date:  2014-03-28       Impact factor: 5.742

4.  Transient or persistent norovirus infection does not alter the pathology of Salmonella typhimurium induced intestinal inflammation and fibrosis in mice.

Authors:  Peter D R Higgins; Laura A Johnson; Kay Sauder; David Moons; Luz Blanco; Stefan Taube; Christiane E Wobus
Journal:  Comp Immunol Microbiol Infect Dis       Date:  2011-01-14       Impact factor: 2.268

5.  Unexpected role of anticoagulant protein C in controlling epithelial barrier integrity and intestinal inflammation.

Authors:  Stefania Vetrano; Victoria A Ploplis; Emanuela Sala; Mayra Sandoval-Cooper; Deborah L Donahue; Carmen Correale; Vincenzo Arena; Antonino Spinelli; Alessandro Repici; Alberto Malesci; Francis J Castellino; Silvio Danese
Journal:  Proc Natl Acad Sci U S A       Date:  2011-11-22       Impact factor: 11.205

6.  Pro-angiogenic activity of TLRs and NLRs: a novel link between gut microbiota and intestinal angiogenesis.

Authors:  Anja Schirbel; Sean Kessler; Florian Rieder; Gail West; Nancy Rebert; Kewal Asosingh; Christine McDonald; Claudio Fiocchi
Journal:  Gastroenterology       Date:  2012-11-10       Impact factor: 22.682

7.  Antiplatelet agents'-ticagrelol and eptifibatide-safety in experimental colitis in mice.

Authors:  Stanko S Petrovic; Milijana M Vasiljevska; Slobodan D Obradovic; Dino K Tarabar; Radoje B Doder; Ivana J Majstorovic; Marijana D Petrovic; Zvonko M Magic; Bojana M Cikota; Nenad J Perisic; Irina A Brcerevic; Nebojsa S Manojlovic; Nemanja K Rancic
Journal:  Turk J Gastroenterol       Date:  2020-06       Impact factor: 1.852

8.  The epithelial danger signal IL-1α is a potent activator of fibroblasts and reactivator of intestinal inflammation.

Authors:  Melania Scarpa; Sean Kessler; Tammy Sadler; Gail West; Craig Homer; Christine McDonald; Carol de la Motte; Claudio Fiocchi; Eleni Stylianou
Journal:  Am J Pathol       Date:  2015-04-10       Impact factor: 4.307

9.  Induction of PIR-A/B+ DCs in the in vitro inflammatory condition and their immunoregulatory function.

Authors:  Fumi Matsui; Muneo Inaba; Kazushige Uchida; Akiyoshi Nishio; Toshiro Fukui; Hideaki Yoshimura; Atsushi Satake; Kazuhiko Yoshioka; Shosaku Nomura; Kazuichi Okazaki
Journal:  J Gastroenterol       Date:  2018-03-05       Impact factor: 7.527

10.  Molecular signaling blockade as a new approach to inhibit leukocyte-endothelial interactions for inflammatory bowel disease treatment.

Authors:  Franco Scaldaferri; Carmen Correale; Antonio Gasbarrini; Silvio Danese
Journal:  Cell Adh Migr       Date:  2009-07-02       Impact factor: 3.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.